Pharmacokinetics of Aripiprazole, a New Antipsychotic, following Oral Dosing in Healthy Adult Japanese Volunteers: Influence of CYP2D6 Polymorphism

We investigated the pharmacokinetics (PK) of aripiprazole, a newly developed antipsychotic, and its active metabolite in healthy Japanese, and the influence of CYP2D6 polymorphism on the PK of aripiprazole. Following a single oral 6mg dose, the mean Cmax, tmax, and t1/2,z (terminal phase half life)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	DRUG METABOLISM AND PHARMACOKINETICS 2007-01, Vol.22 (5), p.358-366
Hauptverfasser:	Kubo, Masanori, Koue, Toshiko, Maune, Hiromi, Fukuda, Tsuyoshi, Azuma, Junichi
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Antipsychotic Agents - administration & dosage Antipsychotic Agents - blood Antipsychotic Agents - pharmacokinetics antipsychotics Aripiprazole Asian Continental Ancestry Group - genetics Biotransformation CYP2D6 genotypes CYP2D641 Cytochrome P-450 CYP2D6 - genetics Cytochrome P-450 CYP2D6 - metabolism Drug Administration Schedule Homozygote Humans Japan pharmacokinetics Phenotype Piperazines - administration & dosage Piperazines - blood Piperazines - pharmacokinetics Polymorphism, Genetic Quinolones - administration & dosage Quinolones - blood Quinolones - pharmacokinetics Reference Values Tablets
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We investigated the pharmacokinetics (PK) of aripiprazole, a newly developed antipsychotic, and its active metabolite in healthy Japanese, and the influence of CYP2D6 polymorphism on the PK of aripiprazole. Following a single oral 6mg dose, the mean Cmax, tmax, and t1/2,z (terminal phase half life) of aripiprazole were 31.0ng/mL, 3.6hr, and 61.0hr, respectively. The t1/2,z in CYP2D6 IM subjects (75.2hr) was significantly (p
ISSN:	1347-4367 1880-0920
DOI:	10.2133/dmpk.22.358